SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology SK bioscience will continue to...
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability Partnership aims to expand affordable and...
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic synergy with SK bioscience Sustainable growth expected, backed by European commercial...
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and...
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026. Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding...